Literature DB >> 20512555

Biology and clinical observations of regulatory T cells in cancer immunology.

Michele W L Teng1, David S Ritchie, Paul Neeson, Mark J Smyth.   

Abstract

This review specifically examines the role of regulatory T cells (Tregs) in cancer in both mice and the clinic. Due to the rapid refinement of the definition of Tregs and their heterogeneity, emphasis is given to research findings over the past three years. For clarity, this review is broadly divided into three short sections that outline the basic biology of Tregs - (1) Treg lineage and development, (2) Treg subsets, and (3) mechanisms of Treg-mediated immune suppression; followed by two more comprehensive sections that cover; (4) clinical observations of Tregs and cancer, and (5) modifications of Treg biology as cancer immunotherapies. The latter two sections discuss the measurement of function and frequency of Treg in model systems and clinical trials and possible ways to interfere with Treg-mediated immune suppression with the focus on recent pre-clinical and clinical findings.

Entities:  

Mesh:

Year:  2011        PMID: 20512555     DOI: 10.1007/82_2010_50

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  17 in total

Review 1.  Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.

Authors:  Margaret K Callahan; Jedd D Wolchok; James P Allison
Journal:  Semin Oncol       Date:  2010-10       Impact factor: 4.929

2.  Carbon nanotubes enhance metastatic growth of lung carcinoma via up-regulation of myeloid-derived suppressor cells.

Authors:  Anna A Shvedova; Alexey V Tkach; Elena R Kisin; Timur Khaliullin; Shyla Stanley; Dmitriy W Gutkin; Alexander Star; Yanan Chen; Galina V Shurin; Valerian E Kagan; Michael R Shurin
Journal:  Small       Date:  2012-09-20       Impact factor: 13.281

3.  The PCa Tumor Microenvironment.

Authors:  Joseph L Sottnik; Jian Zhang; Jill A Macoska; Evan T Keller
Journal:  Cancer Microenviron       Date:  2011-07-05

4.  Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation.

Authors:  C Andrew Stewart; Hannah Metheny; Noriho Iida; Loretta Smith; Miranda Hanson; Folkert Steinhagen; Robert M Leighty; Axel Roers; Christopher L Karp; Werner Müller; Giorgio Trinchieri
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

Review 5.  Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination.

Authors:  Fabian Benencia; Leslee Sprague; John McGinty; Michelle Pate; Maria Muccioli
Journal:  J Biomed Biotechnol       Date:  2012-03-15

Review 6.  Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go.

Authors:  Angela Vasaturo; Stefania Di Blasio; Deborah G A Peeters; Coco C H de Koning; Jolanda M de Vries; Carl G Figdor; Stanleyson V Hato
Journal:  Front Immunol       Date:  2013-12-03       Impact factor: 7.561

7.  TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer.

Authors:  Kaori Sakuishi; Shin Foong Ngiow; Jenna M Sullivan; Michele W L Teng; Vijay K Kuchroo; Mark J Smyth; Ana C Anderson
Journal:  Oncoimmunology       Date:  2013-04-01       Impact factor: 8.110

8.  The interaction between murine melanoma and the immune system reveals that prolonged responses predispose for autoimmunity.

Authors:  Shin Foong Ngiow; Bianca von Scheidt; Andreas Möller; Mark J Smyth; Michele W L Teng
Journal:  Oncoimmunology       Date:  2013-02-01       Impact factor: 8.110

Review 9.  Perspectives on reprograming cancer-associated dendritic cells for anti-tumor therapies.

Authors:  Fabian Benencia; Maria Muccioli; Mawadda Alnaeeli
Journal:  Front Oncol       Date:  2014-04-07       Impact factor: 6.244

10.  Homogeneous expansion of human T-regulatory cells via tumor necrosis factor receptor 2.

Authors:  Yoshiaki Okubo; Toshiyuki Mera; Limei Wang; Denise L Faustman
Journal:  Sci Rep       Date:  2013-11-06       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.